NCT03309462 is a NA clinical trial of Miseq sequencer in Lung Cancer, sponsored by Shanghai Chest Hospital.

Who is sponsoring NCT03309462?

NCT03309462 is sponsored by Shanghai Chest Hospital.

What drugs are being tested in NCT03309462?

Interventions in NCT03309462: Miseq sequencer.

What condition does NCT03309462 study?

NCT03309462 studies Lung Cancer.

Is NCT03309462 still recruiting?

NCT03309462 is currently completed. Last updated 9 December 2019.

Last reviewed 2019-12-09 · How we verify

NCT03309462

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy

Completed NA Last updated 9 December 2019

What this trial tests

NA trial testing Miseq sequencer in Lung Cancer in 50 participants. Completed in 31 July 2019.

Timeline

1 September 2017

Primary endpoint
30 June 2018

31 July 2019

Quick facts

Lead sponsor	Shanghai Chest Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	1 September 2017
Primary completion	30 June 2018
Estimated completion	31 July 2019
Sites	1 location across China

Drugs / interventions tested

Miseq sequencer

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Shanghai Chest Hospital

Who can join

Adults 18 to 80, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to reveal the acquired resistance mechanism of the first and second generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in tissue and plasma using Next Generation Sequencing (NGS) and the difference of ctDNA in plasma and DNA in biopsy samples is compared and the consistency of two samples was observed. At the same time, the sensitivity, specificity and the consistency of detecting T790M mutation using ddPCR, Cobas and NGS were compared.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.
Palacín-Aliana I, García-Romero N, Asensi-Puig A, Carrión-Navarro J, et al · · 2021 · cited 38× · PMID 34440110 · DOI 10.3390/biomedicines9080906
Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y, Xiong L, Xie F, Zheng X, et al · · 2021 · cited 13× · PMID 34173341 · DOI 10.1002/cam4.3948
Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer
Zhang Y, Xiong L, Xie F, Zheng X, et al · · 2020 · DOI 10.21203/rs.3.rs-30958/v1

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03309462 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 9 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03309462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing